Antiparasitic Drugs Market (By Drug Type: Anthelmintic, Antiprotozoal; By Route of Administration: Oral, Injectable, Topical; By Distribution Channel: Hospital pharmacies, Retail pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Antiparasitic Drug Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Antiparasitic Drug Market Revenue and Volume, by Drug Type, 2024-2033
8.1.1 Anthelmintic
8.1.1.1. Market Revenue and Volume Forecast (2021-2033)
8.1.2. Antiprotozoal
8.1.2.1. Market Revenue and Volume Forecast (2021-2033)
9.1. Antiparasitic Drug Market Revenue and Volume, by Route of Administration, 2024-2033
9.1.1. Oral
9.1.1.1. Market Revenue and Volume Forecast (2021-2033)
9.1.2. Injectable
9.1.2.1. Market Revenue and Volume Forecast (2021-2033)
9.1.3. Topical
9.1.3.1. Market Revenue and Volume Forecast (2021-2033)
10.1. Antiparasitic Drug Market Revenue and Volume, by Distribution Channel, 2024-2033
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Volume Forecast (2021-2033)
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Volume Forecast (2021-2033)
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.1.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.1.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.1.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.1.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.1.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.1.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.2.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.2.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.2.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.2.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.2.7.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.3.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.3.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.3.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.3.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.3.7.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.4.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.4.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.4.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.4.7.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.5.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.5.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)
11.5.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.5.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
12.1. GlaxoSmithKline plc
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Merck KGaA
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Novartis AG
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. F. Hoffmann-La Roche Ltd
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client